INmune Bio (NASDAQ:INMB) Issues Quarterly Earnings Results, Beats Expectations By $0.16 EPS

INmune Bio (NASDAQ:INMB) posted its earnings results on Monday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.16, Bloomberg Earnings reports.

INmune Bio stock traded up $0.10 during mid-day trading on Tuesday, hitting $6.21. 509 shares of the stock were exchanged, compared to its average volume of 30,470. INmune Bio has a 12 month low of $5.66 and a 12 month high of $11.50. The firm’s fifty day moving average price is $9.12.

In other news, CEO Raymond Joseph Tesi purchased 10,000 shares of the stock in a transaction on Monday, June 3rd. The stock was purchased at an average price of $6.00 per share, for a total transaction of $60,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Separately, Maxim Group set a $13.00 target price on shares of INmune Bio and gave the stock a “buy” rating in a research report on Monday, June 10th.

INmune Bio Company Profile

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Read More: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with's FREE daily email newsletter.